NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA) announced today that its PGxHealth division has established a Scientific Advisory Board (SAB) of leading experts in the field of cardiovascular genetics to advise PGxHealth on its FAMILION cardiac genetic research and clinical genetic testing. The SAB will provide PGxHealth with a multidisciplinary perspective on emerging molecular diagnostics and therapeutics to help advance the standard of care for inherited heart disease patients. The Board members are joining PGxHealth at the American Heart Association (AHA) meeting in Orlando, FL, to discuss additional opportunities for educating and promoting inherited heart disease research to the healthcare community.
